QIAGEN acquires additional PCR licenses from Ro...

Expanded IP portfolio includes rapidly growing HRM applications for
                    all markets and applications

Venlo, The Netherlands, September 17, 2009 --- QIAGEN (NASDAQ:  QGEN;
Frankfurt, Prime Standard: QIA), today announced that it has acquired
additional licenses from Roche (SIX: RO, ROG; OTCQX: RHHBY) and Idaho
Technology related to  the use  of instrumentation  and reagents  for
PCR-based molecular testing. Financial details were not disclosed.

The agreements cover thermal  cycler rights and real-time  polymerase
chain  reaction  (PCR)   methods  for  diagnostics   and  all   other
applications. In addition, the agreements also cover rights for "high
resolution melting curve analysis"  (HRM) technology. This novel  PCR
technology, which is  well leveraged by  QIAGEN's detection  platform
Rotor-Gene(TM) Q,  opens up  a broad  array of  applications such  as
mutation discovery, pathogen detection  and methylation analysis,  as
it adds a  further information dimension  into traditional real  time
PCR.

With these  agreements QIAGEN  becomes  the first  Idaho  Technology/
Roche licensee to have full freedom to offer HRM related  instruments
and reagents under  license in all  formats and for  all purposes  in
research  and  diagnostics   worldwide.  The  agreements   complement
previous settlement arrangements following QIAGEN's 2008  acquisition
of Australian PCR cycler manufacturer Corbett.

"This additional IP portfolio  enables us to  develop and market  PCR
solutions based on  of the most  advanced technologies for  molecular
diagnostics. HRM allows additional differentiation for genotyping and
can  be  extremely  well  leveraged  on  our  Rotor-Gene(TM)  Q   HRM
instrument",  said   Achim   Ribbe,   Executive   Director   Business
Development for  QIAGEN. "We  now have  a PCR  intellectual  property
estate that we believe is truly unique. It puts us in the position to
offer our customers in molecular diagnostics, pharma, applied testing
and life science research  the latest PCR  technology running on  the
most  versatile  platform  and  covering  all  markets  and   fields,
including human in vitro diagnostics."

QIAGEN also  announced  it  has already  launched  and  is  currently
releasing new  HRM  products  capitalizing on  the  complete  license
portfolio as well as QIAGEN's own intellectual property, including  a
range of  HRM PCR  Kits and  a new  software solution  for HRM  based
genotyping. The Company is preparing submissions of the Rotor-Gene  Q
and related sample and assay technologies for regulatory approval  in
both the US and Europe.

About Thermal Cyclers and PCR:
Thermal cyclers  are the  key instruments  for performing  polymerase
chain reactions  (PCR).  PCR,  used in  life  science  and  molecular
diagnostics, is a process in which  a segment of a nucleic acid  (DNA
or RNA) is copied or "amplified" so that the nucleic acid can be more
readily analyzed. In  real-time PCR,  the amplified  DNA is  detected
during, rather than at  the end of, the  PCR process, a feature  that
facilitates greater  accuracy  in important  applications,  including
pathogen detection, gene expression  quantization and genotyping.  In
2008, QIAGEN acquired Corbett, manufacturer of the Rotor-Gene system,
which is  considered to  be one  of the  world's most  versatile  and
high-performance PCR  systems, which  provides unmatched  temperature
uniformity and supports the broadest range of applications  including
advanced technologies such as HRM.

About QIAGEN:
QIAGEN   N.V.,    a    Netherlands   holding    company,    is    the
leading global provider of  sample  and  assay  technologies.  Sample
technologies are used to  isolate and process  DNA, RNA and  proteins
from biological samples such  as blood or tissue. Assay  technologies
are used  to  make such  isolated  biomolecules visible.  QIAGEN  has
developed and markets more than 500 sample and assay products as well
as automated solutions for such consumables. The company provides its
products to molecular diagnostics laboratories, academic researchers,
pharmaceutical   and    biotechnology    companies,    and    applied
testing customers for  purposes such  as forensics,  animal  or  food
testing   and   pharmaceutical   process   control. QIAGEN's    assay
technologies  include  one  of  the  broadest  panels  of   molecular
diagnostic tests available worldwide. This panel includes the  digene
HPV Test, which  is regarded as  the "gold standard"  in testing  for
high-risk types of human papillomavirus  (HPV), the primary cause  of
cervical cancer. QIAGEN  employs more  than 3,150 people  in over  30
locations worldwide. Further information about QIAGEN can be found at


http://www.qiagen.com/.

Statements contained in  this release that  are not historical  facts
are  forward-looking  statements,  including  statements  about   our
products, markets, strategy  and operating  results. Such  statements
are  based   on  current   expectations   that  involve   risks   and
uncertainties including, but not  limited to, those associated  with:
management of growth and international operations (including currency
fluctuations and logistics),  variability of  our operating  results,
commercial development  of our  markets (including  applied  testing,
clinical  and  academic  research,  proteomics,  women's   health/HPV
testing and molecular diagnostics), our relationships with customers,
suppliers and strategic partners, competition, changes in technology,
fluctuations  in   demand,  regulatory   requirements,   identifying,
developing and producing integrated products differentiated from  our
competitors'  products,  market  acceptance  of  our  products,   and
integration of  acquired  technologies and  businesses.  For  further
information, refer to our filings with the SEC, including our  latest
Form 20-F.  Information in  this release  is as  of the  date of  the
release, and we undertake no  duty to update this information  unless
required by law.

                                 ###


Contacts:


Dr. Solveigh Mähler              Dr. Thomas Theuringer
Director Investor Relations      Associate Director Public Relations
QIAGEN N.V.                      QIAGEN GmbH
[phone]                [phone]

Albert F. Fleury
Investor Relations North America
QIAGEN N.V.
[phone]

email: [e-mail]             email: [e-mail]


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.